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Abstract: Background: The treatment of breastfeeding mothers with depression raises several dilemmas, including the 
possible risk of drug exposure through breast milk for the infant. This article provides background information and pre-
sents practical advice and recommendations for the clinician dealing with the treatment of depression and related disorders 
in the postpartum period. 
Methods: An electronic search for relevant articles was performed. As the use of tricyclic antidepressants has considerably 
decreased during the last decade and no new information on breastfeeding has emerged for the tricyclics in this period, 
this review exclusively focuses on the newer, non-tricyclic compounds. 
Results: Most newer antidepressants produce very low or undetectable plasma concentrations in nursing infants. The 
highest infant plasma levels have been reported for fluoxetine, citalopram and venlafaxine. Suspected adverse effects have 
been reported in a few infants, particularly for fluoxetine and citalopram.  
Conclusions: Infant exposure of antidepressants through breast milk is generally low to very low. We consider that when 
antidepressant treatment is indicated in women with postpartum depression, they should not be advised to discontinue 
breastfeeding. Paroxetine and sertraline are most likely suitable first-line agents. Although some concern has been ex-
pressed for fluoxetine, citalopram and venlafaxine, we nevertheless consider that if the mother has been treated with one 
of these drugs during pregnancy, breast-feeding could also be allowed during continued treatment with these drugs in the 
postpartum period. However, an individual risk-benefit assessment should always be performed. 
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INTRODUCTION 
  Depression is a common illness among women in the 
postpartum period; a prevalence of 10 to 15 % is often re-
ported [1-3]. During this period, challenges are related to 
caretaking of the newborn infant in addition to the poten-
tially harmful effects of the depression on the mother. De-
pressed mothers may be intrusive or withdrawn and disen-
gaged, and are less sensitively attuned to their infants than 
healthy women [4]. In a study of 112 mother-infant pairs, 
chronic maternal depression in the first year postpartum was 
related to delayed psychomotor development in the infant at 
15 months [5]. Moreover, untreated maternal depression may 
also affect the cognitive and emotional development of the 
infant. Thus, the high prevalence of postpartum depression, 
causing functional impairment in the mother and potential 
disturbances of the mother-infant relationship, makes it   
important to initiate effective, rapid-onset therapies in 
women suffering from this disorder [4, 6-8]. 
  Postpartum anxiety disorders are underemphasized and 
may be even more common than postpartum depression [6]. 
The peak age of onset for anxiety disorders in women corre-
sponds with their childbearing years, and particularly the   
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rates of obsessive-convulsive disorder and generalized anxi-
ety disorder are increased in postpartum women. Due to few 
studies only very limited data are available to guide clinical 
interventions for women with or at risk for having perinatal 
anxiety disorders [9]. Medication with antidepressants, in 
particular selective serotonin reuptake inhibitors, may be 
indicated also in some of these women.  
  The benefits of breastfeeding are well documented, both 
for the infant and the mother [7]. Human milk represents the 
ideal primary source of nutrients and provides better immu-
nological and antioxidant protection than do milk substitutes 
[7, 10, 11]. Therefore, women are strongly encouraged to 
breastfeed when possible [12]. Both the American Academy 
of Pediatrics and the World Health Organisation recommend 
the exclusive use of breast milk for 6 months, with use   
of milk substitutes only for infants who cannot be breastfed 
[12, 13]. 
  The dilemma in the treatment of breastfeeding mothers is 
weighing the potential risk to the infant of antidepressant 
exposure through breast milk against the disadvantage of not 
receiving mother’s milk. A third alternative, to discontinue 
or not commence drug treatment, might be even more harm-
ful, taking into account the risk of not receiving adequate 
treatment for the mother and thereby indirectly also for the 
infant [5, 6]. Specific questions to be answered when decid-
ing how to handle a woman with postpartum depression in-
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maternal depression is not adequately treated? How strong is 
the mother’s desire to breastfeed her infant? What are the 
disadvantages of not receiving mother’s milk for the infant? 
What are the risks for the infant of being exposed to an anti-
depressant through breast milk? Is there any evidence to 
suggest that some antidepressants are more favorable than 
others to use during breastfeeding, and are there sufficient 
data to give conclusive advice for the most recently marketed 
antidepressants? Could any practical strategies be used to 
reduce the drug exposure to the infant? And finally, given 
that there is a (small) risk of adverse effects in the infant due 
to drug exposure and breastfeeding nevertheless is allowed, 
should the infant be monitored in any way? 
  In some cases, non-pharmacological treatment may be an 
option, and women with postpartum depression tend to pre-
fer non-pharmacological treatment instead of using medi-
cines [14]. It has also been shown that women in the postpar-
tum period receive fewer prescriptions of psychotropic drugs 
than do non-breastfeeding women, but although psychother-
apy is effective in the treatment of postpartum depression 
[15], it is not widely available. Thus, there is a risk that 
women not receiving antidepressant treatment would be in-
adequately treated for their illness. One major study showed 
that psychological intervention for post-partum depression 
improved maternal mood in the short term, but that this 
benefit was not superior to spontaneous remission in the long 
run [16].  
  A few studies have specifically addressed the effect of 
antidepressants in the postpartum period. Recent case re-
ports, case series and open trials suggest efficacy in women 
suffering from postpartum depression, although many of 
these trials excluded women who were breastfeeding [14]. 
Several studies have shown improvements in postpartum 
depressive symptoms resulting from treatment with selective 
serotonin reuptake inhibitors (SSRIs), such as sertraline [17], 
fluvoxamine [18] and fluoxetine [19], and the SSRIs are   
thus considered first-line therapy in postpartum depression 
[20]. The SSRI group is also recommended in the treatment 
of postpartum dysthymia, panic disorder, and obsessive-
compulsive disorder [21]. In addition, the serotonin-
noradrenaline reuptake inhibitor (SNRI) venlafaxine has 
been found to reduce the symptoms of postpartum depres-
sion [22].  
  Women with a previous episode of postpartum depres-
sion comprise a high-risk group for subsequent episodes; a 
recurrence risk of about 25% has been reported [23]. The 
findings from a small randomised study comparing sertraline 
and placebo in asymptomatic women with at least one prior 
episode of postpartum depression suggest that postpartum 
depression can be prevented [24], although the result needs 
to be replicated in a larger scale. Psychosocial or psycho-
logical interventions
  have not been shown to significantly 
prevent the risk of developing
 postpartum depression [25].  
  A Cochrane review of antidepressant prevention of post-
partum depression from 2005 concluded that it is not possi-
ble to draw any clear conclusions about the effectiveness of 
antidepressants in preventing postpartum depression [26]. 
The reason was the lack of conclusive evidence, and the 
authors stated that larger trials were needed.  
  In some cases, there is a question of whether an effective 
antidepressant treatment given during pregnancy could be 
continued or not when the mother wants to breastfeed. Dis-
continuing essential antidepressant treatment in the postpar-
tum period should be avoided, and switching to another anti-
depressant might also be problematic in this vulnerable pe-
riod. Thus, the issue of infant safety in the postpartum period 
should preferably be taken into consideration already when 
drug treatment is started in a woman, irrespective of whether 
it is before or during pregnancy.  
  Knowledge about infant effects of antidepressants trans-
ferred via breast milk is mostly based upon case studies and 
small case series. A comprehensive review and pooled 
analysis of antidepressant levels in breast milk and nursing 
infants, including possible adverse effects in the infants, was 
published in 2004 [27]. An update of this review, adding 
new information from the period 2004 - 2008, was published 
in 2009 [7]. The aim of the present article is to take even 
newer data into account, providing aggregated background 
information and presenting practical advice and recommen-
dations for the clinician dealing with the treatment of depres-
sion in the postpartum period. During the last decade, the use 
of tricyclic antidepressants has considerably decreased, 
mostly because they are no longer considered first-line ther-
apy due to their adverse effect profile and toxicity. There-
fore, this review focuses on the newer, non-tricyclic antide-
pressants, i.e. the SSRIs citalopram, escitalopram, fluoxetine, 
fluvoxamine, paroxetine and sertraline, the SNRIs   
venlafaxine and duloxetine, and reboxetine, bupropion and 
mirtazapine. First, we present data on the levels of these   
antidepressants in breast milk and in infant plasma; thereafter 
we discuss the reported short-term and long-term adverse 
effects in infants. Finally, we suggest a number of practical 
recommendations. 
ANTIDEPRESSANT LEVELS IN BREAST MILK 
  Detectable levels have been found in breast milk for all 
antidepressants studied [7, 27-29]. In general, drug concen-
trations in milk parallel those in maternal plasma, but with a 
slight delay. Due to the lipophilicity of the drugs, milk levels 
are typically somewhat higher than the levels in maternal 
plasma. For example for citalopram, the milk/plasma con-
centration ratio, i.e. the ratio between the concentration in 
milk and in maternal plasma, is in the interval 1.2–3.0 [10, 
30]. Notably, the triglyceride levels in milk have been shown 
to influence the drug concentrations. In a study from our 
group, higher triglyceride levels were, as expected, found in 
post-feed milk than in pre-feed milk, with accordingly higher 
drug concentrations in post-feed milk, as shown e.g. for   
citalopram, sertraline and fluoxetine [10]. Consequently, for 
research purposes and when comparing results from different 
studies, it is important to provide information about in which 
phase the milk sample has been obtained.  
  The milk drug concentration can be used to estimate the 
daily drug dose ingested by the infant, assuming an average 
milk intake of 150 ml per kg body weight per day. The infant 
dose per kg body weight can then be expressed as a percent-
age of the maternal dose per kg body weight. When the   
relative dose is below 10%, the exposure could generally   
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10% has therefore been suggested [31]. The 10% limit has 
subsequently also been accepted by organisations such as the 
American Academy of Pediatrics. The relative infant doses 
are close to 10% and in some cases even above 10% for cita-
lopram, fluoxetine and venlafaxine, and somewhat lower for 
escitalopram, whereas the relative infant doses are low for 
fluvoxamine, paroxetine, sertraline, duloxetine, reboxetine, 
bupropion and mirtazapine (Table 1). 
ANTIDEPRESSANT LEVELS IN THE INFANT 
  Obviously, the drug concentration in infant plasma is a 
more direct measure of infant exposure than is the milk con-
centration. Among the SSRIs, paroxetine, fluvoxamine and 
sertraline basically produce undetectable plasma levels. The 
levels of citalopram have been measurable in some infants, 
albeit mostly relatively low. Fluoxetine and venlafaxine pro-
duce the highest infant plasma concentrations [10, 27], in 
some infants up to more than 80% and 30% of the assumed 
therapeutic concentrations in adults, respectively. However, 
such high concentrations are uncommon; e.g. for fluoxetine, 
infant plasma concentrations higher than 10 % of the mater-
nal plasma levels were found in 8 of 36 cases (22 %), only, 
in a review [27]. The other antidepressants have either been 
undetectable (duloxetine, bupropion) or been detected at 
extremely low concentrations (escitalopram, reboxetine, mir-
tazapine) in infant plasma (Table 1). 
  It should be noted that in the cases where high concentra-
tions have been found, the infants have generally been below 
3-4 months of age [32]. The capacity to metabolize drugs is 
generally not fully developed in neonates, but increases 
gradually as the hepatic function matures during the first 3-6 
months postpartum. After this period, measurable infant 
plasma levels would not be expected to occur for any antide-
pressant. On the other hand, in preterm newborns, the meta-
bolic capacity will be even more impaired than in full-term 
neonates. As a consequence of the immature hepatic function 
in neonates and the gradual development of the metabolic 
Table 1.  Infant Doses and Plasma Concentrations of Newer Antidepressants after Excretion in Breast Milk 









Absolute Infant Plasma 
Concentrations (ng/ml) 
Relative Infant Plasma 
Concentrations (%)
4 
Selective serotonin reuptake inhibitors 
Citalopram 80
12 0.14  3-10  Negligible
5  Up to 10
6 
Escitalopram 12 0.04  3-6  <5  <4 
Fluoxetine
7  149  0.14  <12  Up to 100
8  Up to 80
8 
Fluvoxamine 12 0.12  <2  Not  detected
9 - 
Paroxetine 119  0.03  0.5-3  Not  detected
9 - 





13  0.50  6-9  Up to 40  Up to 30 
Duloxetine 6
14 <0.03  <1  Not  detected 
9 - 
Reboxetine 4  0.03  1-3  <5 <2 
Bupropion
11 20
15 0.20  2  Not  detected
9 - 
Mirtazapine 11
16 0.04  0.5-3  0.2 
16 <1 
16 
1 The numbers given here are the sum of the number of cases included in the review by Weissmann et al. [27], the number of cases included in the review by Lanza di Scalea et al. 
[7], and the number of cases obtained from literature published after the Lanza di Scalea review was completed. The new references are shown in footnotes 12-16. 
2 Calculated for an infant with a body weight of 5 kg, and assuming a daily milk intake of 150 ml/kg body weight. 
3 Infant daily dose per kg body weight expressed as a percentage of maternal daily dose per kg body weight. A value below 10 % is generally considered negligible. 
4 Infant plasma concentration expressed either as a percentage of the measured maternal plasma concentration or as a percentage of what could be considered a low therapeutic con-
centration in adults [61].  
5 In most cases below the lower limits of detection for the analytical methods employed, which were mostly in the range of 2–5 ng/ml. However, in a few cases, which also have been 
associated with suspected adverse effects, concentrations up to 15 ng/ml have been found.  
6 In a few cases, which also have been found associated with suspected adverse effects, concentrations up to about 50 % of the therapeutic concentration range have been found. 
7 The values represent the sum of fluoxetine and the active metabolite norfluoxetine.  
8 In some cases, which also have been associated with suspected adverse effects, as high as about 500 ng/ml, i.e., clearly within the therapeutic concentration range. 
9 Below the lower limits of detection for the analytical methods employed, which were mostly in the range of 1–5 ng/ml. 
10 The values represent the sum of venlafaxine and the active metabolite O-desmethylvenlafaxine. 
11 Including one or several of the active metabolites of bupropion. 
12 One new case (cf. footnote 1) is obtained from Werremeyer, 2009 [62]. 
13 Thirteen new cases (cf. footnote 1) are obtained from Newport et al., 2009 [43]. 
14 One new case (cf. footnote 1) is obtained from Briggs et al., 2009 [63]. 
15 Four new cases (cf. footnote 1) are obtained from Davis et al., 2009 [64]. 
16 One new case (cf. footnote 1) is obtained from Tonn et al., 2009 [65]. In this case, the infant plasma concentration was 10 ng/ml, corresponding to about 30 % of the maternal 
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capacity of drugs, infant age is a central factor to take into 
account when performing an individual risk analysis. 
  Genetically determined differences in the metabolic ca-
pacity of hepatic enzymes involved in the metabolism of 
antidepressants may also affect the infant plasma levels. The 
most relevant enzymes with regard to antidepressant metabo-
lism are the polymorphic cytochrome P-450 enzymes 
CYP2D6 and CYP2C19. In a study of 24 lactating mothers 
treated with SSRIs or venlafaxine and their 25 infants, a   
genetically determined impaired capacity to metabolise 
drugs via these enzymes (in the mother and/or the infant) did 
not significantly increase infant exposure [10]. Notably, a 
mother who was a CYP2C19 poor metaboliser and was 
treated with the CYP2C19 substrate citalopram had the high-
est plasma concentration of citalopram among all subjects 
studied. Nevertheless, her twin infants (who both were het-
erozygous extensive CYP2C19 metabolisers) still had ex-
tremely low plasma concentrations of citalopram [10]. 
POSSIBLE ADVERSE EFFECTS IN THE INFANT 
  Whether the low antidepressant concentrations found in 
most infants are able to exert pharmacological effects re-
mains an open question. For the drugs causing the lowest – 
and in many cases even undetectable – levels, such an influ-
ence is unlikely. In two studies attempting to elucidate the 
pharmacodynamic potential of antidepressants in breastfed 
infants, platelet serotonin levels were measured in the infants 
before and during maternal treatment with SSRIs [33, 34].  
In the first study, no differences were observed when   
the mothers were treated with sertraline [33]. In the second 
study, no effects were seen in 10 of 11 infants whose   
mothers were treated with fluoxetine [34]. 
  Adverse events in breastfed infants exposed to newer 
antidepressants through breast milk have been suspected in a 
few cases, and more often after exposure to fluoxetine and 
citalopram than after exposure to other drugs [7, 27, 35-40]. 
The effects observed have mostly been subtle and unspecific, 
and may even have arisen by coincidence. For example, cry-
ing, irritability, decreased feeding and watery stools have 
been described in a few cases for fluoxetine [35-37]. For 
citalopram, hypotonia, colic, decreased feeding and sleep 
difficulties have been reported in single cases [38, 39]. For 
other SSRIs the observations are even scantier [40]. Al-
though single case reports are difficult to interpret with re-
gard to causality it is interesting to note that the number of 
reports is higher for the drugs showing the highest infant 
plasma levels, i.e. citalopram and fluoxetine. For ven-
lafaxine, which also has a relatively high infant exposure, no 
adverse events have been reported [10, 41-43], but the total 
number of exposed infants is considerably lower for ven-
lafaxine than for e.g. citalopram and fluoxetine (Table 1). 
  A single case of seizures has been reported in a 6-month-
old breastfed infant after 4 days of maternal bupropion 
treatment [44]. Although seizures are a well-known adverse 
effect of bupropion, the relationship remains obscure, par-
ticularly as the infant was relatively old and had a respiratory 
tract infection, and as the levels of bupropion and/or active 
metabolites were not documented, neither in milk nor in the 
infant.  
  Based on known adverse reactions after therapeutic use 
of SSRIs and previously suspected adverse events in breast-
fed infants we developed a questionnaire of infant symptoms 
to be filled in by the mothers [10]. The questionnaire was 
completed by 20 mothers treated with SSRIs or venlafaxine 
and well as by a control group of 68 medication-free breast-
feeding mothers. The questionnaire included signs such as 
sneezing, regurgitation or vomiting, loud crying, decreased 
sleep, increased sleep, irritability, tremor, decreased muscle 
tone, and suckling or feeding problems. There were no   
significant differences in any symptoms between the two   
groups [10].  
  Another study has compared the frequency of possible 
adverse events in 31 infants whose mothers were treated 
with citalopram, 7 infants whose mothers were treated with 
other SSRIs, 5 infants whose mothers were treated with non-
SSRIs and 31 infants of healthy mothers not taking any 
medication [39]. There were no significant differences in the 
frequency of signs reported in the infants between the groups 
(3/31, 0/12 and 1/31, respectively). Nevertheless, the three 
infants in the citalopram group presented with decreased 
feeding, colic and irritability, respectively, which have been 
suspected as adverse effects also in other reports [38, 39]. 
  A specific safety index for antidepressant use in breast-
feeding mothers has been proposed [40]. The index is ex-
pressed as the ratio between the reported number of infants 
with adverse events after exposure to an antidepressant 
through milk and the reported total number of exposed in-
fants for the same antidepressant, multiplied by 100. It is 
suggested that a value 2 indicates that the drug is relatively 
safe; a value of 2.1-10 indicates that the drug should be used 
with great caution, and a value above 10 indicates that the 
drug should be contraindicated in breastfeeding mothers. The 
index has some limitations, such as that it is less reliable 
when the number of cases in the literature is low, and that it 
does not take into consideration the quality of raw data, e.g. 
whether the suspected adverse events most likely have arisen 
by coincidence or whether the relationship to drug exposure 
more likely is causal. Finally, there is a risk that the numbers 
found are abnormally high, as one could expect that there are 
numerous exposures without any adverse effects that have 
not been reported in the literature, whereas the reporting rate 
is considerably higher for infants where possible adverse 
effects were observed. By applying the safety index on the 
cases reported before 2007, the calculated values were 0.68 
and 0.95 for sertraline and paroxetine, and 3.5 and 5.3 for 
fluoxetine and citalopram, respectively [40]. These differ-
ences in safety index values between the various drugs   
are consistent with what would be expected from literature 
reviews applying more qualitative investigative approaches 
[7, 27].  
  In conclusion, even though antidepressants probably have 
been subject to more published data then any other drug 
class (cf. Table 1) there is, with a few exceptions, little evi-
dence for causality between exposure through breast milk 
and adverse events in the infants [45]. 
THE POTENTIAL RISK OF LONG-TERM EFFECTS  
  Several studies have investigated the possible effect of 
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during the first year of life. In a study of 78 nursing infants 
whose mothers were treated with SSRIs (n=75) or ven-
lafaxine (n=3), there were no differences in body weight 
compared to values from normative populations [46]. In   
a study on 11 infants exposed to citalopram, there were no 
differences in body weight after 12 months compared to 10 
infants of medication-free mothers [47]. Finally, in a study 
on 27 infants exposed to paroxetine, there were no differ-
ences in body weight at 6 and 12 months compared to 27 
breastfeed and 19 bottle-feed infants of medication-free 
mothers [48]. 
  Long-term nevrobehavioural data on infant antidepres-
sant exposure through breast milk is generally lacking. Such 
studies are also methodologically challenging, as the longer 
follow-up time, the greater influence would other factors, 
such as maternal mental health, be expected to have on the 
infant, relative to the role of drug exposure through breast 
milk. Although there is a lack of data concerning exposure 
through breast milk, some long-term information is available 
after antidepressant exposure in utero [47-52]. In these stud-
ies, no detrimental long-term effects were revealed for fac-
tors such as global intelligence quotient, language, behav-
ioural development and neurological development. In a re-
cent study in four-year-old children investigated by the Child 
Behaviour Check List [53], maternal mood was found to be 
more predictive of internalising behaviours than prenatal 
exposure to psychotropic drugs. Moreover, in another study 
no differences in externalising behaviours were detected 
between four-year-old children exposed to SSRIs during 
pregnancy and a non-exposed group [54]. These results are 
reassuring, as antidepressant exposure in utero causes serum 
concentrations that are at least 5- to 10-fold higher than ex-
posure through breast milk [47, 52, 55].  
CLINICAL RECOMMENDATIONS  
  Several attempts to guide clinical decisions regarding 
breast-feeding during treatment with antidepressants have 
been made, including some more comprehensive reviews 
and overviews [7, 27, 29, 40, 45]. Also scientific organisa-
tions have attempted to develop practical guidelines [56-58], 
but two of these guidelines [56, 58] put more focus on drug 
treatment during pregnancy than in the postpartum period 
and are relatively vague with regard to the choice of specific 
drugs in lactating women.  
  Most of the reviews and guidelines recommend that the 
choice of specific treatment should be based upon an indi-
vidual risk-benefit analysis. In such an analysis both the risk 
of untreated maternal illness for the mother and the infant, 
the risk/benefit of the specific treatment for the mother and 
the infant, the risk/benefit of being breastfed or not for the 
infant, the possible maternal risks of renouncing breastfeed-
ing, and the mother’s desire to breastfeed should be taken 
into consideration. Medication exposure may involve a risk 
for the infant, but there are also risks both with an untreated 
depression and of not receiving mother’s milk for the infant. 
Therefore, no clinical decision in the context of postpartum 
depression is completely risk-free [59]. 
  Non-pharmacological interventions such as psychother-
apy should be considered, particularly for mild to moderate 
depression. For women with moderate to severe depression 
and in some cases also with anxiety disorder, medications 
are generally the most appropriate choice of treatment. 
Moreover, for women with previous postpartum depression 
or women who have been treated with antidepressants during 
pregnancy, antidepressants are the preferred mode of treat-
ment in the prophylaxis or new episodes/relapses.  
  Regarding the choice of specific antidepressant, it is usu-
ally recommended that paroxetine and sertraline should be 
preferred over other SSRIs due to the low infant exposure for 
these drugs (Table 1) [7, 29, 40, 57]. However, paroxetine 
might have some disadvantages related to the treatment of 
women in fertile age in general. First, if the mother needs 
long-term treatment and subsequently becomes pregnant 
once again, paroxetine is probably not the first choice due to 
the risk of cardiac defects. Second, the risk of withdrawal 
symptoms might be higher than for other SSRIs if one or a 
few doses are missed (which possibly might occur more of-
ten among busy, and perhaps even sleep-deprived, post-
partum mothers than among other women). 
  It is often recommended that when possible, fluoxetine 
and citalopram should be avoided or used with caution due 
to the higher infant plasma levels than for other drugs and 
the possible risk of adverse effects in the infant [7, 29, 40]. 
However, if the mother has been treated with fluoxetine or 
citalopram previously and the treatment was effective, or if 
the mother has used one of these drugs during pregnancy, it 
could also be used in the postpartum period [7, 29]. In a 
study from our group including various SSRIs and ven-
lafaxine [10], we concluded that when antidepressant treat-
ment is indicated in the postpartum period, the women 
should generally not be advised to discontinue breastfeeding. 
  The numbers of exposed cases vary significantly between 
drugs, with about 100 cases for fluoxetine, paroxetine, ser-
traline and citalopram, but less than 25 for the other newer 
antidepressants (Table 1). Some degree of uncertainty inevi-
tably exists for the drugs with the lowest numbers of exposed 
infants, also when no adverse effects have been reported. On 
this basis, drugs for which little data exist, such as fluvoxam-
ine, venlafaxine, duloxetine, reboxetine, bupropion and mir-
tazapine, should not be considered as first-line therapies, but 
they can be used in special cases [7, 29, 57].  
  Some of the reviews and guidelines recommend infant 
monitoring, particularly if the infant is sick, premature or has 
a low body weight [7, 27, 57]. However, given the very low 
risk of infant effects and the unspecific nature of possible 
infant symptoms, we consider there is no general need for 
regular and specific follow-up examinations [29].  
  Routine breast milk and/or infant serum sampling for 
drug concentration analysis is generally not recommended 
[7, 27, 45]. It can, however, be helpful if the infant has signs 
that may be indicative of drug exposure [57]. In addition, it 
is our experience that it is often reassuring for a mother who 
has a strong desire to continue breastfeeding to know that the 
drug is found in negligible concentrations in milk and/or 
infant plasma. Thus, arguments exist to perform milk or in-
fant plasma drug analyses more liberally than often recom-
mended, at least when such analyses are easily available. 
  As antidepressants are lipophilic drugs, their excretion in 
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[10, 60]. Yet, the nutritional value of human milk is also 
linked to its triglyceride levels. Therefore, any effort to avoid 
the rather minimal additional drug exposure imposed by 
breast milk containing high vs. low triglyceride levels cannot 
be recommended [10]. 
  Most antidepressants have long elimination half-lives and 
their levels in breast milk generally vary relatively little dur-
ing a dose interval. Consequently, avoiding breastfeeding 
during the peak concentration phase, e.g. by taking the daily 
drug dose in the evening and avoiding breastfeeding during  
the night, will only reduce the infant drug intake to a small 
extent.  
  Pumping and discarding breast milk to reduce the expo-
sure is of little value. First, there is no indication that there is 
a risk threshold that is crossed if the infant exposure is re-
duced to some extent, e.g. by 30-50%. Second, discarding 
breast milk implicitly implies that drug exposure is detrimen-
tal if the infant is feeded by breast milk, only. Third, in our 
experience, a procedure of e.g. 50% breast-feeding and 50% 
bottle-feeding most often ends with bottle-feeding, only, 
after a relatively short period of time. 
CONCLUSION 
  Postpartum depression is a potentially serious condition 
in need of effective treatment. Several modalities of inter-
vention may be helpful, and both psychotherapy and treat-
ment with antidepressants are recommended.  
  Data from a large number of studies show that antide-
pressants differ with respect to infant exposure. Available 
data are clearly homogenous with this respect, showing that 
in the SSRI group, paroxetine and sertraline are excreted in 
milk in low amounts that do not produce measurable concen-
trations in infant plasma, and these drugs have neither been 
associated with clear-cut adverse effects in the infant. On the 
other hand, fluoxetine and citalopram are excreted in milk in 
higher amounts, which in a few cases have caused significant 
plasma levels in the infant and suspected adverse effects. For 
other newer antidepressants, data are scarce, with relatively 
few exposed infants reported. Of these drugs, preliminary 
data indicate that venlafaxine causes somewhat higher infant 
exposure than the other drugs. 
  Taking all current knowledge into consideration, we   
suggest that when antidepressant treatment is indicated in 
women with postpartum depression, they should generally 
not be advised to discontinue breastfeeding. With regard to 
choice of specific agent, paroxetine and sertraline should be 
considered first. Nevertheless, although some concern has 
been expressed for fluoxetine, citalopram and venlafaxine, 
we consider that if the mother has been treated with one of 
these drugs during pregnancy, breast-feeding could generally 
also be allowed during continued treatment with these drugs 
instead of switching to a “safer” drug. However, these drugs, 
in addition to drugs for which very little information exist, 
should not be considered first-line agents if there are not 
specific reasons for preferring them. 
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